Indo US Bio-Tech Ltd (INDOUS) — shareholding pattern, promoter holding, financials and share price
About Indo US Bio-Tech Ltd (INDOUS)
Indo US Bio-Tech Ltd operates in the Other Agricultural Products industry, within the Fast Moving Consumer Goods sector. It trades on the NSE as INDOUS and on the BSE under scrip code 541304. Its ISIN is INE250Z01010.
Incorporated in 2004, Indo US Bio-Tech Ltd is engaged in production and processing of commercial and vegetable seeds [1]
Indo Us Bio-Tech Limited is a leading seed company in India, focused on crop research, breeding, and seed production.
Originally established as Pollucid Bio-Tech in 2004, the company underwent several name changes before becoming a public limited company in 2018.
Listed peers in Other Agricultural Products: BharatRohan Airborne Innovations Ltd, JK Agri Genetics Ltd, Mangalam Seeds Ltd, Harshdeep Hortico Ltd, Nagarjuna Agri Tech Ltd, Puretrop Fruits Ltd.
Valuation & Returns
10 Jul 2026At ₹87.8 a share on 10 Jul 2026, Indo US Bio-Tech Ltd (INDOUS) was valued at a price-to-earnings ratio of 13.42x against an industry P/E of 33.81x and a price-to-book of 2.24x on a book value of ₹39.16 per share as of Mar 2025. Solomo computes return on equity of 16.71% and return on capital employed of 17.31% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 13.42x
- Industry P/E
- 33.81x
- P/B
- 2.24x
- EPS (TTM)
- ₹6.54
- Book value / share
- ₹39.16
- ROE
- 16.71%
- ROCE
- 17.31%
- ROA
- 13.41%
- Debt / equity
- 0.19x
- Dividend yield
- 0.29%
- EBITDA margin
- 15.46%
- 52-week range
- ₹85.66 – ₹205.1
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2022In the year ended Mar 2022, Indo US Bio-Tech Ltd (INDOUS) reported revenue of ₹49.39 crore, net profit of ₹5.06 crore and earnings per share of ₹2.77. That compares with revenue of ₹39.39 crore and net profit of ₹4.9 crore in Mar 2021. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹26.02 crore and net profit ₹1.97 crore (standalone).
| Metric | Mar 2020 | Mar 2021 | Mar 2022 |
|---|---|---|---|
| Revenue (₹ cr) | 39.76 | 39.39 | 49.39 |
| Net profit (₹ cr) | 2.53 | 4.9 | 5.06 |
| EPS (₹) | 1.74 | 3.38 | 2.77 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 21.17% | 27.54% | 24.81% |
| Profit growth | 45.04% | 45.91% | 3.27% |
| Stock price CAGR | 28% | -18% | -46% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 68.29% of Indo US Bio-Tech Ltd (INDOUS) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0.01%. Market capitalisation was ₹176 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Jun 2018.
Largest disclosed public shareholders in Jun 2026: IMPROWISED TECHNOLOGIES PRIVATE 1.99%, HUF 1.82%, BHARTIBEN RAJENDRA GANDHI 1.5%, PRATIK RAJENDRABHAI GANDHI 1.5%, AUMIT CAPITAL ADVISORS LIMITED 1.19%, NATVARSINH T CHAVDA . 1.02%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 68.29% | - | 0.01% | - | 31.71% |
| Mar 2026 | 68.29% | - | 0.18% | - | 31.71% |
| Dec 2025 | 70.17% | - | - | - | 29.83% |
| Sep 2025 | 70.17% | - | - | - | 29.83% |
| Jun 2025 | 70.17% | - | - | - | 29.83% |
| Mar 2025 | 70.17% | - | 0% | - | 29.83% |
| Dec 2024 | 70.17% | - | 0% | - | 29.83% |
| Sep 2024 | 70.17% | - | - | - | 29.83% |